Navigation Links
Perdue Kidd & Vickery Wins First Humira Trial - Abbott Laboratories To Pay $2.24 Million
Date:5/9/2013

CHICAGO, May 9, 2013 /PRNewswire/ -- Today, a Cook County jury entered a verdict finding Abbott Laboratories negligent and ordering it to pay $2,244,063.20 to Plaintiff Milton Tietz on behalf of his wife, Delores Tietz . The court entered judgment in that sum, plus costs, in favor of the Plaintiff.  This is the first Humira lawsuit filed against Abbott to go to trial.

"Humira has dangerous side effects and Abbott was negligent regarding them.  Justice has been done," said Tietz attorney Andy Vickery of Perdue Kidd & Vickery.

"We are honored that a jury of twelve people looked at the evidence and agreed that Abbott failed to do what the law requires," said Tietz attorney Jim M. Perdue, Jr.    

Delores Tietz was prescribed Humira, a TNF Blocker, for rheumatoid arthritis in October 2009 and took the drug for close to seven months, before almost dying. In early May 2010, Delores began experiencing chest pain and fevers.  Her illness went undiagnosed for weeks, and her family was told it was probable that she would not survive.  Finally, doctors diagnosed her with Humira-induced disseminated histoplasmosis, a severe, life-threatening infection. 

The FDA issued an alert in September 2008 to all manufacturers of TNF blockers, including Abbott Laboratories, to provide new information to the medical community about the risks of unrecognized, drug-induced histoplasmosis.  Abbott failed to send a letter directly to physicians warning of the danger until May 17, 2010, 20 months after the initial FDA alert and 10 days after Mrs. Tietz was hospitalized.  The jury found that Abbott was negligent for not taking reasonable measures to make sure Delores' doctors had a high index of suspicion for histoplasmosis. 

Milton Tietz is represented by Jim M. Perdue Jr. , Arnold Anderson Vickery and Fred Shepherd of Perdue Kidd & Vickery, and Gary D. McCallister of Gary D. McCallister & Associates LLC.

Perdue Kidd & Vickery is a national law firm of Personal Injury and Drug Injury Trial Lawyers.  The firm represents individuals and businesses across the country who have been harmed personally and financially.  Perdue Kidd & Vickery is based in Houston, Texas. For more information about Perdue Kidd & Vickery, visit www.perduekiddvickery.com or call 713-520-2500.    


'/>"/>
SOURCE Perdue Kidd & Vickery
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
2. Smith & Nephew launches revolutionary open-architecture suture anchor for rotator cuff repair with greater pullout strength than competitors[i]
3. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
4. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
5. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
8. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
9. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
10. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
11. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... May 24, 2016 Celsion Corporation (NASDAQ: ... company, today provided an update on its ongoing ... trial combining GEN-1, the Company,s DNA-based immunotherapy, with ... newly-diagnosed patients with advanced ovarian cancer who will ... GEN-1 is an IL-12 DNA plasmid vector formulated ...
(Date:5/24/2016)... 24, 2016 The innovator ... , s first dual therapy stent, introduces ... OrbusNeich, a global company specializing in the ... to include products to treat peripheral artery disease. The ... entry devices for lower limb and arteriovenous (AV) fistula ...
(Date:5/24/2016)... 24, 2016 ... , la première endoprothèse à double thérapie ... l,intervention portant sur les membres inférieurs et ... OrbusNeich, entreprise mondiale spécialisée dans la fourniture ... vie, a élargi son portefeuille pour inclure ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... ... services to provide one resource, from start to finish, for Life Safety compliance. ... Statement of Condition surveys requested by the Joint Commission, and fire stopping reviews, ...
(Date:5/24/2016)... ... May 24, 2016 , ... Jericho Project has named LaToya Williams-Belfort to ... be responsible for fundraising and communications for the nationally-acclaimed nonprofit, working closely with CEO ... working to end homelessness at its roots. , “LaToya Williams-Belfort is joining Jericho ...
(Date:5/24/2016)... ... May 24, 2016 , ... Educational opportunities, and ... with more advantaged communities providing richer opportunities. Recognizing the key role of housing ... improvement policies; (b) school choice policies; (c) school desegregation policies; (d) wealth-focused policies; ...
(Date:5/24/2016)... ... May 24, 2016 , ... New Brunswick, New Jersey: This year marks ... reach their fullest potential. To commemorate the anniversary, the hospital has themed the milestone ... Roll for Children’s Specialized Hospital Foundation on Saturday, May 21, at Johnson Park in ...
(Date:5/24/2016)... ... (PRWEB) May 24, ... new members of its Advisory Board. Joining the Grow Healthy ... “All three of them embody the mission of our organization and ... fortunate to have them as we continue to expand our footprint ...
Breaking Medicine News(10 mins):